JP2021506786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506786A5 JP2021506786A5 JP2020532551A JP2020532551A JP2021506786A5 JP 2021506786 A5 JP2021506786 A5 JP 2021506786A5 JP 2020532551 A JP2020532551 A JP 2020532551A JP 2020532551 A JP2020532551 A JP 2020532551A JP 2021506786 A5 JP2021506786 A5 JP 2021506786A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- cdr
- antibody
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023177190A JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | ＦｃＲｎ抗体およびその使用方法 |
| JP2025089576A JP2025143252A (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598402P | 2017-12-13 | 2017-12-13 | |
| US62/598,402 | 2017-12-13 | ||
| US201862701354P | 2018-07-20 | 2018-07-20 | |
| US62/701,354 | 2018-07-20 | ||
| PCT/US2018/065568 WO2019118791A1 (en) | 2017-12-13 | 2018-12-13 | Fcrn antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177190A Division JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | ＦｃＲｎ抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021506786A JP2021506786A (ja) | 2021-02-22 |
| JP2021506786A5 true JP2021506786A5 (https=) | 2021-05-13 |
| JP7420720B2 JP7420720B2 (ja) | 2024-01-23 |
Family
ID=65041911
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532551A Active JP7420720B2 (ja) | 2017-12-13 | 2018-12-13 | ＦｃＲｎ抗体およびその使用方法 |
| JP2023177190A Active JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | ＦｃＲｎ抗体およびその使用方法 |
| JP2025089576A Pending JP2025143252A (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177190A Active JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | ＦｃＲｎ抗体およびその使用方法 |
| JP2025089576A Pending JP2025143252A (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11773168B2 (https=) |
| EP (1) | EP3723802A1 (https=) |
| JP (3) | JP7420720B2 (https=) |
| KR (2) | KR102904658B1 (https=) |
| CN (1) | CN111712259A (https=) |
| AU (1) | AU2018386193B2 (https=) |
| BR (1) | BR112020011310A2 (https=) |
| CA (1) | CA3085751A1 (https=) |
| IL (1) | IL275070A (https=) |
| NZ (1) | NZ765250A (https=) |
| SG (1) | SG11202005021PA (https=) |
| WO (1) | WO2019118791A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64768B1 (sr) | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals Inc | Fcrn antitela i načini njihove upotrebe |
| CA3081144A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) * | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| CN113518783A (zh) | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
| EP4007605A4 (en) * | 2019-08-01 | 2023-08-16 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
| JP2023509195A (ja) | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
| AU2021292200A1 (en) * | 2020-06-17 | 2023-02-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
| IL302516A (en) * | 2020-11-06 | 2023-07-01 | Janssen Biotech Inc | FCRN antibodies and methods of using them |
| US20240182598A1 (en) * | 2021-04-12 | 2024-06-06 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating pediatric myasthenia gravis |
| CN116234827A (zh) * | 2021-09-03 | 2023-06-06 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| CN114129730A (zh) * | 2021-09-16 | 2022-03-04 | 宁夏大学 | FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用 |
| KR20240134900A (ko) * | 2022-01-17 | 2024-09-10 | 아르젠엑스 비브이 | 자가항체 매개 질환 환자를 치료하기 위한 방법 |
| CN119698429A (zh) | 2022-06-15 | 2025-03-25 | 阿根思有限公司 | Fcrn结合分子及使用方法 |
| WO2025008537A1 (en) | 2023-07-05 | 2025-01-09 | Ablynx Nv | Improved fcrn antagonists for treatment of igg-related diseases and disorders |
| CN121909214A (zh) | 2023-07-31 | 2026-04-21 | 玫帝托克斯股份有限公司 | 一种抗体及包含该抗体的用于治疗免疫疾病的药物组合物 |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025186787A1 (en) * | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101721362B (zh) | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| CA2534973A1 (en) | 2003-08-08 | 2005-02-17 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| ES2569409T3 (es) | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| US20110059101A9 (en) | 2006-03-13 | 2011-03-10 | Ablynx N.V. | Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling |
| WO2009131702A2 (en) | 2008-04-25 | 2009-10-29 | Dyax Corp. | Antibodies against fcrn and use thereof |
| CN102549016B (zh) | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| ES2765874T3 (es) * | 2011-05-25 | 2020-06-11 | Innate Pharma Sa | Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios |
| AU2012262007B2 (en) | 2011-06-02 | 2017-06-22 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| ES2802274T3 (es) | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Glicoproteínas sialiladas |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| PL3137504T3 (pl) | 2014-04-30 | 2023-10-16 | Hanall Biopharma Co., Ltd. | Przeciwciało wiążące się z FcRn do leczenia chorób autoimmunologicznych |
| RS64768B1 (sr) | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals Inc | Fcrn antitela i načini njihove upotrebe |
| EP3294335B1 (en) * | 2015-05-12 | 2023-07-05 | Syntimmune Inc. | Humanized affinity matured anti-fcrn antibodies |
| SMT202400004T1 (it) | 2016-07-29 | 2024-03-13 | Momenta Pharmaceuticals Inc | Anticorpi fcrn e loro metodi di utilizzo |
| JP6913527B2 (ja) | 2017-06-22 | 2021-08-04 | 株式会社小松製作所 | 油圧ポンプおよびモータ |
| CA3081144A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| WO2019160979A1 (en) | 2018-02-13 | 2019-08-22 | The Brigham And Women's Hospital, Inc. | Therapeutic fcrn-based bispecific monoclonal antibodies |
| WO2020023310A1 (en) | 2018-07-20 | 2020-01-30 | Williams Eva | Compositions of fcrn antibodies and methods of use thereof |
| CN113518783A (zh) | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
| CN113646051A (zh) | 2018-10-16 | 2021-11-12 | Ucb生物制药有限责任公司 | 重症肌无力的治疗方法 |
| EP4007605A4 (en) | 2019-08-01 | 2023-08-16 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
| IL302516A (en) | 2020-11-06 | 2023-07-01 | Janssen Biotech Inc | FCRN antibodies and methods of using them |
-
2018
- 2018-12-13 KR KR1020207019955A patent/KR102904658B1/ko active Active
- 2018-12-13 AU AU2018386193A patent/AU2018386193B2/en active Active
- 2018-12-13 KR KR1020257042733A patent/KR20260008175A/ko active Pending
- 2018-12-13 WO PCT/US2018/065568 patent/WO2019118791A1/en not_active Ceased
- 2018-12-13 SG SG11202005021PA patent/SG11202005021PA/en unknown
- 2018-12-13 NZ NZ765250A patent/NZ765250A/en unknown
- 2018-12-13 JP JP2020532551A patent/JP7420720B2/ja active Active
- 2018-12-13 US US16/771,147 patent/US11773168B2/en active Active
- 2018-12-13 BR BR112020011310-7A patent/BR112020011310A2/pt unknown
- 2018-12-13 CA CA3085751A patent/CA3085751A1/en active Pending
- 2018-12-13 CN CN201880089334.7A patent/CN111712259A/zh active Pending
- 2018-12-13 EP EP18836751.0A patent/EP3723802A1/en active Pending
-
2020
- 2020-06-02 IL IL275070A patent/IL275070A/en unknown
-
2023
- 2023-08-18 US US18/452,346 patent/US20240158509A1/en active Pending
- 2023-10-13 JP JP2023177190A patent/JP7690538B2/ja active Active
-
2025
- 2025-05-29 JP JP2025089576A patent/JP2025143252A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506786A5 (https=) | ||
| JP2024016042A5 (https=) | ||
| JP2019526540A5 (https=) | ||
| JP7442575B2 (ja) | Ｆｃｒｎ抗体及びその使用方法 | |
| US20240132603A1 (en) | Ccr8 antibody and application thereof | |
| KR100255717B1 (ko) | 항체의 생산방법 | |
| JP7420720B2 (ja) | ＦｃＲｎ抗体およびその使用方法 | |
| WO2020060924A1 (en) | Use of a cd4/cd8 bispecific antibody for the treatment of autoimmune/inflammatory disorders | |
| ES2389781T3 (es) | Tratamiento de la inflamación articular crónica mediante un anticuerpo aglicosilado anti-CD3 | |
| US20220144946A1 (en) | Fcrn antibodies and methods of use thereof | |
| US20140199299A1 (en) | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists | |
| JP2025138661A (ja) | Ｆｃｒｎ抗体およびその使用の方法 | |
| BR112020012011A2 (pt) | moléculas de ligação a antígeno biespecífica isolada e de ligação a antígeno biespecífica ou cadeia de imunoglobulina, composição farmacêutica, recipiente ou dispositivo de injeção, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, métodos para tratar uma doença ou condição, para tratar uma condição de lipodistrofia em um sujeito, para produzir uma molécula de ligação a antígeno biespecífica, e, para administrar uma molécula de ligação a antígeno biespecífica isolada ou composição farmacêutica. | |
| EA028678B1 (ru) | Нейтрализующие пролактиновый рецептор антитела и их терапевтическое применение | |
| US8367061B2 (en) | Anti-idiotype monoclonal antibodies mimicking the HIV gp120 CD4-binding (CD4bs) | |
| ES2274542T3 (es) | Anticuerpos frente al receptor del interferon alfa/beta. | |
| ES3001197T3 (es) | Agente de unión anti-adrenomedulina (ADM) para su uso en la terapia o prevención de síntomas de enfermedad | |
| WO2015098813A1 (ja) | 新規抗ヒトｂｄｃａ－２抗体 | |
| CN105770889B (zh) | 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用 | |
| US12103969B2 (en) | Anti-Siglec antibody, pharmaceutical composition comprising the same, and uses thereof | |
| JPH11263799A (ja) | 受精能を変化させる方法 | |
| JP7654849B2 (ja) | 抗ｒａｎｋｌ抗体およびその使用 | |
| ES2835923T3 (es) | Anticuerpo antiesclerostina, fragmento de unión a antígeno y uso médico del mismo | |
| AU2017225906A1 (en) | Methods of treating bone diseases, disorders and/or injuries and reagents therefor | |
| JP2021522795A (ja) | ＴＧＦβ−スーパーファミリーのリガンドの新規バインダーおよびその使用 |